Navigation Links
Spectros T-Stat Tissue Oximeter Clinical Studies Presented at PAS (Pediatric Academic Societies') Conference
Date:5/19/2009

PORTOLA VALLEY, Calif., May 19 /PRNewswire/ -- Spectros announced today that its T-Stat Tissue Oximeter was featured in two presentations at the Pediatric Academic Societies' (PAS) annual conference held in Baltimore, Maryland, May 2-5, 2009. The studies focused on clinical applications of the Spectros T-Stat monitor in the neonatal intensive care unit (NICU).

The first abstract was titled, "Visible Light Spectroscopy (VLS) for Detecting Alterations in Tissue Oxygenation with PRBC Transfusion in Very Low Birth Weight (VLBW) Neonates." The authors noted, "VLS is an easy to use and noninvasive method of assessment of tissue saturation in VLBW neonates with various severity of illness."

The second poster was titled, "Noninvasive Measurements of Plasma Bilirubin Levels Using Real-Time Visible Light Spectroscopy." The authors concluded visible light spectroscopy can be used as a method to measure real-time plasma bilirubin levels noninvasively. This compliments prior studies showing T-Stat can measure tissue or plasma met-hemoglobin and carboxy-hemoglobin.

"The utilization and acceptance of T-Stat has grown tremendously over the past 16 months as clinicians have increasingly recognized the need to monitor tissue perfusion in a reliable, reproducible, and quantitative way," commented Michael Fierro, Director of Clinical Studies. "We have additional studies in progress and will continue to demonstrate the efficacy of the T-Stat in reducing hospitalization costs and improving outcome in this high-risk population."

About Spectros

Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's lead product, the T-Stat Tissue Oximeter, was the first medical device FDA-approved as sensitive to ischemia, an insufficient blood flow to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art visible light spectroscopy (VLS) technology. In clinical use, T-Stat is a real-time, absolute, noninvasive, and continuous tissue monitor that analyzes 260 wavelengths of light, far more than the 2-4 wavelengths used in other monitors for superior accuracy.

Spectros is also developing molecular diagnostic tools for breast and prostate cancer currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are for investigational use only. T-Stat is a registered trademark of the Spectros Corporation.)


'/>"/>
SOURCE Spectros
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Fluorescent glass SRMs are new tool for spectroscopy
2. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
3. Spectros Corporation Protects Its Cool White LED Spectroscopy Technology Against Alleged Infringement by Thermo Fisher Scientific
4. New Edition of Definitive Resource in Tissue Engineering Released Today
5. BioLife Solutions CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells
6. TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction
7. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
8. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
9. The closest look ever at native human tissue
10. Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology
11. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global ... industries to improve patient outcomes and quality of life, will now be offering ... being attributed to new regulatory requirements for all new drug products, including the ...
(Date:10/11/2017)... USA (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s ... take place on 7th and 8th June 2018 in San Francisco, CA. The Summit ... as well as several distinguished CEOs, board directors and government officials from around the ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published in ... and fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched ... , After comparing the results from the fresh and frozen transfer cohorts, the ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
Breaking Biology News(10 mins):